{
    "id": 6946,
    "fullName": "FLT3 R834Q",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 R834Q lies within the protein kinase domain of the Flt3 protein (UniProt.org). R834Q results in constitutive phosphorylation of Flt3, activation of Erk signaling, and is transforming in culture (PMID: 18068628).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2803,
                    "pubMedId": 18068628,
                    "title": "Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18068628"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "R834Q",
    "createDate": "06/02/2015",
    "updateDate": "10/04/2018",
    "referenceTranscriptCoordinates": {
        "id": 144563,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28018507C>T",
        "cDna": "c.2501G>A",
        "protein": "p.R834Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2285,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 R834Q in culture (PMID: 18068628).",
            "molecularProfile": {
                "id": 6799,
                "profileName": "FLT3 R834Q"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2803,
                    "pubMedId": 18068628,
                    "title": "Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18068628"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2286,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD98059 inhibited ERK1/2 phosphorylation and reduced cell growth in transformed cells expressing FLT3 R834Q (PMID: 18068628).",
            "molecularProfile": {
                "id": 6799,
                "profileName": "FLT3 R834Q"
            },
            "therapy": {
                "id": 2617,
                "therapyName": "PD98059",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2803,
                    "pubMedId": 18068628,
                    "title": "Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18068628"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4807,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R834Q were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19275,
                "profileName": "FLT3 exon 14 ins FLT3 R834Q"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4808,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/R834Q mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19276,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 R834Q"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6799,
            "profileName": "FLT3 R834Q",
            "profileTreatmentApproaches": [
                {
                    "id": 5025,
                    "name": "FLT3 Inhibitor",
                    "profileName": "FLT3 R834Q"
                }
            ]
        },
        {
            "id": 19275,
            "profileName": "FLT3 exon 14 ins FLT3 R834Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19276,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 R834Q",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144563,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28018507C>T",
            "cDna": "c.2501G>A",
            "protein": "p.R834Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}